bromfenac

Steroid and NSAID combination prevents macular oedema after cataractsA combination of a topical corticosteroid and a nonsteroidal anti-inflammatory drug (NSAID) is more effective than either one alone in reducing the risk of cystoid macular oedema (CME) after cataract surgery in nondiabetic patients, researchers say.
Changing the game in treatment of acute pseudophakic CMEJoshua Mali, MD, provides clinical evidence and recommendations for pseudophakic CME and represents a new formal standard to first-line management.
Selecting topical regimens for cataract patients
Selecting topical regimens for cataract patientsEyecare practitioners who deal with patients in the perioperative period are well aware of the need for topical therapy. In most cases, a combination of a steroid, a nonsteroidal anti-inflammatory drug (NSAID), and an antibiotic will be used for a few days before the day of surgery and then for a period afterward.
Bausch + Lomb receives FDA approval for ProlensaProlensa (bromfenac ophthalmic solution) 0.07% has received FDA approval for treating postop inflammation and ocular pain reduction following cataract surgery.
B + L, CROMA donate eye dropsBausch + Lomb and CROMA have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox) to projects in Africa sponsored by Light for the World.